三氧化二砷巩固治疗使儿童急性早幼粒细胞白血病患者蒽环类药物剂量得以降低:儿童肿瘤学组III期历史对照试验AAML0631报告
AAML0631是一项III期历史对照试验,纳入101例(标危66例、高危35例)初诊儿童急性早幼粒细胞白血病(APL)患者,在巩固期采用三氧化二砷(ATO)治疗并降低蒽环类药物剂量。3年总生存率为94%,无事件生存率(EFS)为91%;标危与高危患者的总生存率分别为98%和86%(P=.003)。标危患者的EFS不劣于使用更高蒽环剂量且未含ATO巩固的历史对照AIDA 0493。
要点
- ATO巩固方案在儿童APL中耐受良好,并允许显著降低蒽环类药物的累积剂量。
- 3年总生存率94%,EFS 91%;标危与高危患者的总生存率分别为98%和86%(P=.003)。
- 自巩固1结束(ATO治疗后)起,3年复发风险仅4%,标危与高危患者间无显著差异。
核心结论
- ATO巩固治疗在儿童APL中耐受良好,允许显著降低蒽环类累积剂量,同时标危和高危患者均维持优异的生存和低复发风险。
研究设计与样本
- 儿童肿瘤学组AAML0631为III期历史对照试验,纳入2至21岁经PML-RARα聚合酶链反应确诊的初诊APL患者101例(标危66例、高危35例),按诊断时白细胞计数分层。
主要发现
- 101例可评估患者3年总生存率为94%,EFS为91%;标危与高危患者总生存率98% vs 86%(P=.003),EFS 95% vs 83%(P=.03)。
- AAML0631标危患者的EFS不劣于AIDA 0493历史对照,后者使用了显著更高的蒽环剂量且未包含ATO巩固。
- 自巩固1结束(ATO治疗后)起,AAML0631患者3年复发风险仅4%,标危与高危患者间无显著差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The Children's Oncology Group AAML0631 trial for newly diagnosed pediatric acute promyelocytic leukemia (APL) was a phase III historically controlled trial to determine the survival of patients receiving arsenic trioxide (ATO) consolidation and reduced doses of anthracyclines. Patients and Methods Patients age 2 to 21 years with de novo APL confirmed by PML-RARα polymerase chain reaction were stratified as standard risk (SR) or high risk (HR) on the basis of diagnostic WBC count. All patients received all-trans retinoic acid (ATRA) during induction, each consolidation course, and maintenance. All patients received two cycles of ATO therapy during consolidation 1, an additional two (SR) or three (HR) consolidation courses that included high-dose cytarabine and anthracycline, and maintenance therapy comprising ATRA, oral methotrexate, and mercaptopurine. Results One hundred one patients (66 SR and 35 HR) were evaluable for outcome. The 3-year overall survival was 94%, and event-free survival (EFS) was 91%. For SR and HR patients with APL, the overall survival was 98% versus 86% ( P = .003), and EFS was 95% versus 83% ( P = .03), respectively. The EFS for SR patients in AAML0631 was noninferior to that of patients in the AIDA 0493 historical control, which used a significantly higher anthracycline dose and did not include ATO consolidation. Relapse risk for patients in AAML0631 from end consolidation 1 (after ATO treatment) was only 4% at 3 years and did not differ significantly between SR and HR patients. Conclusion ATO consolidation cycles were well tolerated in pediatric patients with APL and allowed significant reduction in cumulative anthracycline doses while maintaining excellent survival and a low relapse risk for both SR and HR patients with APL.
引用
- Kutny MA, Alonzo TA, Gerbing RB, et al. Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. J Clin Oncol. 2017. PMID: 28767288. doi:10.1200/JCO.2016.71.6183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。